2026-04-18T16:02:32.901Z / 美国有线电视新闻网（CNN）
作者：亚历杭德拉·哈拉米略
3小时前
发布于 2026年4月18日 美国东部时间12:02
当地时间4月18日，华盛顿特区白宫椭圆形办公室，总统唐纳德·特朗普签署一项行政令，放宽包括伊博格碱在内的心理健康治疗相关限制。
内森·霍华德/路透社
美国总统唐纳德·特朗普于周六签署一项行政令，旨在推动扩大致幻剂药物研究，这是其探索新兴心理健康治疗方案整体举措的一部分。
“在许多案例中，这些实验性治疗为饱受严重精神疾病和抑郁症困扰的患者——包括我们尊敬的退伍军人——带来了改变人生的潜力，”特朗普在椭圆形办公室的签署仪式上说道。
总统同时宣布，联邦政府将投入5000万美元，用于伊博格碱的进一步研究。
在签署该行政令前，特朗普提及了他所称的证明该药物潜力的初步研究，并打趣称自己也想试用一下。
“能给我来点吗？我想来点，”特朗普说道，还补充说他愿意“不惜一切代价尝试”，这番话引得椭圆形办公室内一片笑声。“我没时间抑郁。你知道吗，要是足够忙碌，或许这也管用。这就是我现在的状态。”
当地时间4月18日，华盛顿特区白宫椭圆形办公室，唐纳德·特朗普总统手持一项有关放宽心理健康治疗限制的行政令，该行政令包含伊博格碱相关内容，是他当日签署的文件之一。
内森·霍华德/路透社
总统邀请了卫生与公众服务部部长小罗伯特·F·肯尼迪等人发表讲话，其中包括伊博格碱的支持者、播客主持人乔·罗根。
罗根曾在2024年支持特朗普，但近期因反对总统的多项政策——包括其对伊朗战争的处理方式——登上新闻头条。他表示，自己与总统的沟通促成了这项政策出台。
“我想告诉所有人这件事是如何发生的，”罗根在椭圆形办公室说道，“我给特朗普总统发了一些相关资料。”
“他回复的短信是，‘听起来不错，你想要FDA批准吗？那就这么办吧’，”罗根补充道，整个过程“简直快得离谱”。
肯尼迪表示，此举是应对全国心理健康危机整体努力的一部分。
“卫生与公众服务部将加快新型心理健康治疗方案的研究审批和获取渠道，包括致幻疗法，借此做出这一决定性举措，以应对我国面临的最紧迫公共卫生挑战之一：心理健康危机，”肯尼迪说道。
“这项行政令将消除大多数阻碍美国研究人员、科学家、医生和临床医生正当研究这些药物的法律障碍，并在适当时机为其安全治疗用途建立规范流程，”他补充道。
该行政令还旨在加快某些致幻剂治疗方案的审批进度，美国食品药品监督管理局（FDA）局长马蒂·马卡里博士表示，在新举措下，审批流程可以大幅提速。
“如果符合我国国家优先事项，药物审批可以在数周内完成，而非一年或一年以上，而是数周，”马卡里在椭圆形办公室说道。
伊博格碱未获FDA批准
2024年竞选期间，肯尼迪曾表示，他的儿子和几位朋友曾使用致幻剂来应对创伤和抑郁症。他在7月对国会表示，致幻剂“如果在临床环境下使用，将具有巨大优势，我们正在全力确保在12个月内实现这一目标”。
然而，科学家们担忧本届政府将绕过医学研究的严格标准，可能将患者置于风险之中。
伊博格碱尚未获得FDA批准，但在一些国家被用于治疗阿片类药物戒断症状。数十年来，它一直被列为第一类管制物质，这类物质被定义为目前尚无公认医疗用途且具有高滥用潜力的药品。
这种从中非 iboga 植物中提取的化合物，已被用于降低阿片类药物成瘾者的渴求感，并治疗退伍军人的抑郁症、焦虑症和创伤后应激障碍症状。
早期研究表明，伊博格碱可能会改变某些神经通路，有望改善部分心理健康状况。
这种致幻剂已知会增加心律异常的风险，还可能引发呕吐。已有多起与摄入伊博格碱相关的死亡案例，但并不总能明确是药物本身、潜在健康状况还是其他因素直接导致了死亡。
伊博格碱是行政令中唯一被点名提及的致幻剂，但 LSD、MDMA 以及“神奇蘑菇”中的活性成分裸盖菇素，在美国也已被研究用于治疗创伤后应激障碍和抑郁症。
小型临床试验表明，在治疗环境下给予一到两次裸盖菇素剂量，可对难治性重度抑郁症患者产生显著且持久的改善。这类患者通常对传统抗抑郁药物无反应。基于此项研究，FDA 将裸盖菇素认定为突破性疗法，该类别旨在加快审查尚未获批的、用于治疗严重或危及生命疾病的实验性药物。
2024年，一款用于治疗广泛性焦虑症的 LSD 制剂获得突破性疗法认定，目前正处于进一步试验阶段。
同样在2024年，FDA 拒绝批准 MDMA 用于治疗创伤后应激障碍，要求药物赞助商提供更多临床试验数据。该机构的一个咨询委员会对此前开展的试验的完整性表示担忧，并表示很难判断伴随的谈话疗法对参与者的结果产生了多大影响。
CNN 的凯瑟琳·迪林杰、卡尼塔·耶尔、桑迪·拉莫特和米哈尔·鲁普雷希特为本报道撰稿。
Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’
2026-04-18T16:02:32.901Z / CNN
By Alejandra Jaramillo
3 hr ago
PUBLISHED Apr 18, 2026, 12:02 PM ET
President Donald Trump signs an executive order about easing restrictions on mental health treatments, including, ibogaine, in the Oval Office of the White House in Washington, DC, on April 18.
Nathan Howard/Reuters
President Donald Trump on Saturday signed an executive order aimed at encouraging expanded research into psychedelic drugs, part of a broader push to explore emerging mental health treatments.
“In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,” Trump said during a signing event in the Oval Office.
The president also announced that the federal government is making a $50 million investment for further research into the psychedelic drug ibogaine.
Trump, ahead of signing the order, pointed to initial research he said demonstrates the drug’s potential and quipped that he wanted some himself.
“Can I have some, please? I’ll take some,” Trump said, adding that he would “take whatever it takes,” prompting laughter in the Oval. “I don’t have time to be depressed. You know, if you stay busy enough, maybe that works, too. That’s what I do.”
President Donald Trump holds an executive order about easing restrictions on mental health treatments, including, ibogaine, which he signed, in the Oval Office of the White House in Washington, DC, on April 18.
Nathan Howard/Reuters
The president invited Health and Human Services Secretary Robert F. Kennedy Jr. and others, including podcast host Joe Rogan, a supporter of ibogaine, to speak about the initiative.
Rogan, who backed Trump in 2024 but has recently made headlines for his opposition to some of the president’s policies, including his handling of the Iran war, said his outreach to the president helped spark the policy move.
“I want to tell everybody how this happened,” Rogan said from the Oval Office. “I sent President Trump some information.”
“The text message that came back,” Rogan said, “’sounds great, do you want FDA approval? Let’s do it,’” he added that it was “literally that quick.”
Kennedy said the move is part of a broader effort to address the nation’s mental health crisis.
“HHS will accelerate research approval and access to new mental health treatments, including psychedelic therapies, such as for taking this decision, this decisive step to confront one of the most urgent public health challenges facing our nation, the mental health crisis,” Kennedy said.
“This executive order for most legal impediments that block American researchers, scientists, physicians and clinicians improperly studying these medicines and, where appropriate, establishing protocols for their safe therapeutic use,” he added.
The order also aims to accelerate the approval timeline for certain psychedelic-based treatments, with US Food and Drug Administration Commissioner Dr. Marty Makary saying the process could move far faster under the new initiative.
“Drugs can get approved in weeks, not a year or a year-plus but in weeks, if they are in line with our national priorities,” Makary said in the Oval Office.
Ibogaine lacks FDA approval
On the campaign trail in 2024, Kennedy said his son and several friends used psychedelic drugs to deal with trauma and depression. He told Congress in July that psychedelics have “tremendous advantage if given in a clinical setting, and we are working very hard to make sure that happens within 12 months.”
However, scientists have expressed concern that the administration will bypass the rigorous benchmarks of medical research and potentially put patients at risk.
Ibogaine has not been approved by the FDA, but it’s used in some countries to treat opioid withdrawal symptoms. It’s been classified as a Schedule I substance, a designation for substances with no currently accepted medical use and a high potential for abuse, for decades.
The compound — extracted from the iboga plant in Central Africa — has been used to decrease opioid cravings and treat depression, anxiety and post-traumatic stress disorder symptoms in veterans.
Early research suggests that ibogaine may alter certain neural pathways, potentially leading to improvements in some mental health conditions.
The hallucinogen is known to raise the risk of abnormal heart rhythms and rates and could cause vomiting. Several deaths have been associated with the ingestion of ibogaine, though it’s not always clear whether the drug itself, underlying health conditions or other factors were the direct cause.
Ibogaine is the only psychedelic mentioned by name in the executive order, but LSD, MDMA and psilocybin – the active ingredient in “magic mushrooms” – have also been studied in the US as treatments for post-traumatic stress disorder and depression.
Small clinical trials have shown that one or two doses of psilocybin, given in a therapeutic setting, can make dramatic and long-lasting changes in people with treatment-resistant major depressive disorder, which typically does not respond to traditional antidepressants. Based on this research, the FDA has designated psilocybin as a breakthrough medicine, a category created to speed the process for reviewing not-yet-approved experimental medicines intended to treat serious or life-threatening conditions.
A formulation of LSD to treat generalized anxiety disorder received breakthrough therapy status in 2024 and is undergoing further trial.
Also in 2024, the FDA declined to approve MDMA as a treatment for PTSD, requesting additional clinical trials from the drug’s sponsor. An agency advisory committee expressed concerns about the integrity of the trials that had been previously conducted and said it was hard to tell how much the accompanying talk therapy had influenced the participants’ outcomes.
CNN’s Katherine Dillinger, Kaanita Iyer, Sandee LaMotte and Michal Ruprecht contributed to this report.